Nachrichten zur Eli Lilly & Co Aktie

WDH/ROUNDUP: US-Pharmakonzern Lilly hebt ein weiteres Mal das Umsatzziel

(In der Überschrift wurden fehlende Buchstaben beim Wort weiteres ergänzt.) INDIANAPOLIS (dpa-AFX) -…

Were raising our price target on Eli Lilly as the obesity-drug boom rolls on

The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And theres more growth to be had.…

Stocks making the biggest moves midday: ADT, Alphabet, Caterpillar, Eli Lilly, Chipotle & more

These are the stocks posting the largest moves midday.…

ROUNDUP: US-Pharmakonzern Lilly hebt ein weites Mal das Umsatzziel

INDIANAPOLIS (dpa-AFX) - Der Pharmakonzern Lilly kann sich weiterhin auf den Gewichtssenker Zepbound und das…

Market movers: Microsoft, Alphabet, Marvell, Eli Lilly, Phunware...

…

US-Pharmakonzern Lilly hebt ein weites Mal das Umsatzziel

INDIANAPOLIS (dpa-AFX) - Der Pharmakonzern Lilly kann sich weiterhin auf den Gewichtssenker Zepbound und das…

GLP-1-Dynamik hält an: Eli Lilly hebt Umsatzprognose nach starkem Quartal kräftig an

Operative Rekordzahlen: Im dritten Quartal kletterte der Konzernumsatz auf 24, 4 Milliarden US-Dollar, während das Ergebnis je Aktie mit…

Stocks making the biggest moves premarket: Alphabet, Caterpillar, Eli Lilly, DoorDash & more

These are the stocks posting the largest moves in the premarket.…

Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.…

Eli Lilly shares jump 6% as drugmaker lifts 2026 revenue forecast

Eli Lilly and Co (NYSE:LLY) shares rose more than 6% on Thursday morning after the drugmaker raised its full-year revenue…

Eli Lilly jumps on earnings beat, raised guidance

Eli Lilly jumps on earnings beat, raised guidance…

Whats in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?

Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q326 results.…

Goldman Sachs resets Eli Lilly 12-month stock price target before earnings

Wall Street expects strong numbers from LLY, but Goldman says one figure will decide the reaction.…

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in…

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -1.33% move from the previous day.…

Is Eli Lilly Stock a Buy Right Now?

…

Eli Lilly – Foundayo vor EU-Zulassung: Neue Chancen im weltweiten 114-Mrd.-USD-Abnehmboom

Die EMA empfiehlt Foundayo gegen Adipositas und Typ-2-Diabetes. Ein EU-Start ist noch 2026 möglich. Retatrutide erreicht bis zu 28,3…

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lillys Next Leg Higher

Eli Lillys greatest strength isnt Zepbound. It is the companys drug discovery engine.…

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

A new government-funded study found that GLP-1 drugs slow the aging process in mice.…

Eli Lilly – Warum ich nach dem Ausbruchsversuch weiter Lilly statt Novo Nordisk bevorzuge

Die Rotation aus Technologieaktien in den Gesundheitssektor macht Eli Lilly (LLY) erneut interessant. Charttechnisch zeigt sich Lilly als klarer Leader-Stock…

Eli Lilly won the first round of the weight-loss boom. Who wins next?

Eli Lilly dominated the first wave of GLP-1s. Now new treatments and shifting consumer spending are creating opportunities beyond the…

Eli Lilly Reports Earnings on Oct. 29. Heres Why the Retatrutide Story Matters More Than the Quarter.

Eli Lillys next big growth driver could be bigger than Zepbound.…

Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.

Lillys recent retreat isnt a sign of a broken investment thesis.…

Better Pharma ETF: iShares IHE vs. State Street XPH

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower…

Eli Lilly-backed TRex Bio closes day flat after IPO

…

Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell

Eli Lillys GLP-1 momentum, new drugs and M&A deals support growth, while pricing pressure and competition pose headwinds.…

Eli Lillys Obesity Business Could Become a Much Bigger Healthcare Platform

…

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lillys revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple,…

FDA Expands Eli Lillys Blood Cancer Drug Label in First-Line Setting

LLYs Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.…

Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study

One-third of all new patients starting an oral GLP-1 medication are now choosing Foundayo.…

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity…

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

JNJ trades at a 28% discount on valuation while LLYs cardiometabolic drugs drive 82% of revenue, each bet carries distinct…

Could Eli Lillys Newest Weight Loss Strategy Pay Off for Decades?

The company is constantly thinking big.…

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide…

Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights

In the most recent trading session, Eli Lilly (LLY) closed at $1, indicating a -2.33% shift from the previous trading…

Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Heres How the News Could Shake Up the Obesity Drug Market.

Phase three trials on Eli Lillys new weight loss drug, TRIUMPH-2, showed strong results.…

dpa-AFX ProFeed